A number of medicines have been granted provisional consents over the years, under both National and Labour Governments, and it's clear that the provisional approval or consent power clearly has value for New Zealand. And, again, the reasons for that are discussed in the judgment, including the fact that under a provisional consent, further information can be required to be provided by the provider of the medicine as a condition of the provisional consent, in a way which is not as clear in respect of final consents, and, therefore, it is often desirable that a provisional consent be granted on those terms because it can't be granted on those terms for a final consent. That, obviously, is something that probably she looked at more broadly, and already the Minister of Health has made it clear that there will be a new Therapeutic Products Bill introduced to replace the Medicines Act, which will look at that more holistically. 